Full year revenue and EBITDA in line with market expectations despite challenging and changing COVID-19 testing marketLeveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years http://novacyt.com/wp-content/uploads/2022/04/Novacyt-Full-year-2021-results-and-update-on-growth-strategy.pdf
Visit PageYear: 2022
Informations sur le litige avec le DHSC
Paris, France et Camberley, Royaume-Uni – 26 avril 2022 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce une mise à jour de son litige en cours avec le Department of Health and Social Care (“DHSC”). http://novacyt.com/wp-content/uploads/2022/04/Novacyt-Informations-sur-le-litige-avec-le-DHSC.pdf
Visit PageDHSC dispute update
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”). http://novacyt.com/wp-content/uploads/2022/04/Novacyt-DHSC-dispute-update-1.pdf
Visit Page